Blood Test Identifies Heart Failure with Preserved Ejection Fraction
By LabMedica International staff writers Posted on 12 Nov 2018 |
Image: A photomicrograph of heart cells (Photo courtesy of Cedars-Sinai Medical Center).
A test based on a protein biomarker found in the blood is the basis of a scoring system that distinguishes patients with clinical heart failure with preserved ejection fraction (HFpEF) from healthy individuals and patients with risk factors but no heart failure.
Heart failure with preserved ejection fraction is a growing epidemic worldwide with a high burden of morbidity and mortality. Lack of understanding of the pathology and physiology of the syndrome has limited development of diagnostic tools to define and follow the disease progression.
Cardiac bridging integrator 1 (cBIN1) is a membrane-scaffolding protein in cardiomyocytes that organizes the dyad-containing microdomains at the transverse tubules that are responsible for the initiation and regulation of systolic and diastolic calcium transients. The level of cBIN1 is reduced in animal models of heart failure, as well as in human biopsy samples from patients with end-stage cardiomyopathy. Its blood availability makes it an attractive biomarker of cardiomyocyte remodeling.
Investigators at Cedars-Sinai Medical Center (Los Angeles, CA, USA) determined cBIN1 scores (CS) from ELISA measurement of plasma cBIN1 concentrations from 52 stable, ambulatory patients with HFpEF from age-matched and sex-matched healthy individuals and participants with heart failure risk factors but no HFpEF. The analysis examined the ability of the CS and N-terminal pro-B-type natriuretic peptide (NT-proBNP) results to differentiate among the patients.
Results revealed that the CS values were significantly higher in the patients with HFpEF than in the two control cohorts. For patients with HFpEF, the CS outperformed NT-proBNP when the comparator group was either healthy control participants or those with risk factors. Thus, the plasma CS, a marker of transverse tubule dysfunction, serves as a biomarker of cardiomyocyte remodeling that has the potential to aide in the diagnosis of HFpEF.
"By the time heart failure symptoms develop, the critical window for corrective therapy has typically closed," said senior author Dr. Robin Shaw, professor of medicine at Cedars-Sinai Medical Center. "Our discovery allows us to not only diagnose the disease sooner, but also to treat patients before that critical period of early intervention for lifesaving care has closed."
The study was published in the October 31, 2018, online edition of the journal JAMA Cardiology.
Related Links:
Cedars-Sinai Medical Center
Heart failure with preserved ejection fraction is a growing epidemic worldwide with a high burden of morbidity and mortality. Lack of understanding of the pathology and physiology of the syndrome has limited development of diagnostic tools to define and follow the disease progression.
Cardiac bridging integrator 1 (cBIN1) is a membrane-scaffolding protein in cardiomyocytes that organizes the dyad-containing microdomains at the transverse tubules that are responsible for the initiation and regulation of systolic and diastolic calcium transients. The level of cBIN1 is reduced in animal models of heart failure, as well as in human biopsy samples from patients with end-stage cardiomyopathy. Its blood availability makes it an attractive biomarker of cardiomyocyte remodeling.
Investigators at Cedars-Sinai Medical Center (Los Angeles, CA, USA) determined cBIN1 scores (CS) from ELISA measurement of plasma cBIN1 concentrations from 52 stable, ambulatory patients with HFpEF from age-matched and sex-matched healthy individuals and participants with heart failure risk factors but no HFpEF. The analysis examined the ability of the CS and N-terminal pro-B-type natriuretic peptide (NT-proBNP) results to differentiate among the patients.
Results revealed that the CS values were significantly higher in the patients with HFpEF than in the two control cohorts. For patients with HFpEF, the CS outperformed NT-proBNP when the comparator group was either healthy control participants or those with risk factors. Thus, the plasma CS, a marker of transverse tubule dysfunction, serves as a biomarker of cardiomyocyte remodeling that has the potential to aide in the diagnosis of HFpEF.
"By the time heart failure symptoms develop, the critical window for corrective therapy has typically closed," said senior author Dr. Robin Shaw, professor of medicine at Cedars-Sinai Medical Center. "Our discovery allows us to not only diagnose the disease sooner, but also to treat patients before that critical period of early intervention for lifesaving care has closed."
The study was published in the October 31, 2018, online edition of the journal JAMA Cardiology.
Related Links:
Cedars-Sinai Medical Center
Latest Molecular Diagnostics News
- Blood Proteins Could Warn of Cancer Seven Years before Diagnosis
- New DNA Origami Technique to Advance Disease Diagnosis
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells
- New Respiratory Syndromic Testing Panel Provides Fast and Accurate Results
- New Synthetic Biomarker Technology Differentiates Between Prior Zika and Dengue Infections
- Novel Biomarkers to Improve Diagnosis of Renal Cell Carcinoma Subtypes
- RNA-Powered Molecular Test to Help Combat Early-Age Onset Colorectal Cancer
- Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia
- Multi-Omic Noninvasive Urine-Based DNA Test to Improve Bladder Cancer Detection
- First of Its Kind NGS Assay for Precise Detection of BCR::ABL1 Fusion Gene to Enable Personalized Leukemia Treatment
- Urine Test to Revolutionize Lyme Disease Testing
- Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease
- New Genetic Testing Procedure Combined With Ultrasound Detects High Cardiovascular Risk
- Blood Samples Enhance B-Cell Lymphoma Diagnostics and Prognosis
- Blood Test Predicts Knee Osteoarthritis Eight Years Before Signs Appears On X-Rays
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans